These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1041 related articles for article (PubMed ID: 27883117)

  • 1. Combination therapies for improved management of lower urinary tract symptoms/benign prostatic hyperplasia.
    De Nunzio C; Presicce F; Tubaro A
    Drugs Today (Barc); 2016 Sep; 52(9):501-517. PubMed ID: 27883117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?
    Silva J; Silva CM; Cruz F
    Curr Opin Urol; 2014 Jan; 24(1):21-8. PubMed ID: 24231531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Effectiveness of Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis.
    Dahm P; Brasure M; MacDonald R; Olson CM; Nelson VA; Fink HA; Rwabasonga B; Risk MC; Wilt TJ
    Eur Urol; 2017 Apr; 71(4):570-581. PubMed ID: 27717522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of PDE5 inhibitors alone or in combination with alpha-blockers for the treatment of erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta-analysis.
    Yan H; Zong H; Cui Y; Li N; Zhang Y
    J Sex Med; 2014 Jun; 11(6):1539-45. PubMed ID: 24621088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association].
    Descazeaud A; Robert G; Delongchamps NB; Cornu JN; Saussine C; Haillot O; Devonec M; Fourmarier M; Ballereau C; Lukacs B; Dumonceau O; Azzouzi AR; Faix A; Desgrandchamps F; de la Taille A;
    Prog Urol; 2012 Dec; 22(16):977-88. PubMed ID: 23178093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study.
    Cindolo L; Pirozzi L; Fanizza C; Romero M; Tubaro A; Autorino R; De Nunzio C; Schips L
    Eur Urol; 2015 Sep; 68(3):418-25. PubMed ID: 25465970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical therapy for benign prostatic hyperplasia: a review.
    Van Asseldonk B; Barkin J; Elterman DS
    Can J Urol; 2015 Oct; 22 Suppl 1():7-17. PubMed ID: 26497339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.
    Gacci M; Eardley I; Giuliano F; Hatzichristou D; Kaplan SA; Maggi M; McVary KT; Mirone V; Porst H; Roehrborn CG
    Eur Urol; 2011 Oct; 60(4):809-25. PubMed ID: 21726934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of a Fixed-Dose Combination Therapy of Tamsulosin and Tadalafil for Patients With Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Randomized, Double-Blinded, Active-Controlled Trial.
    Kim SW; Park NC; Lee SW; Yang DY; Park JK; Moon DG; Yang SK; Lee SW; Moon KH; Ahn TY; Kim SW; Park K; Min KS; Ryu JK; Son H; Jung J; Hyun JS
    J Sex Med; 2017 Aug; 14(8):1018-1027. PubMed ID: 28760246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.
    Pattanaik S; Mavuduru RS; Panda A; Mathew JL; Agarwal MM; Hwang EC; Lyon JA; Singh SK; Mandal AK
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD010060. PubMed ID: 30480763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.
    Pattanaik S; Mavuduru RS; Panda A; Mathew JL; Agarwal MM; Hwang EC; Lyon JA; Singh SK; Mandal AK
    BJU Int; 2019 Jul; 124(1):27-34. PubMed ID: 30681264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms.
    Jin R; Strand DW; Forbes CM; Case T; Cates JMM; Liu Q; Ramirez-Solano M; Milne GL; Sanchez S; Wang ZY; Bjorling DE; Miller NL; Matusik RJ
    Prostate; 2021 Sep; 81(13):944-955. PubMed ID: 34288015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of phosphodiesterase type 5 inhibitors for lower urinary tract symptoms.
    Miller MS
    Ann Pharmacother; 2013 Feb; 47(2):278-83. PubMed ID: 23386068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
    Gacci M; Corona G; Salvi M; Vignozzi L; McVary KT; Kaplan SA; Roehrborn CG; Serni S; Mirone V; Carini M; Maggi M
    Eur Urol; 2012 May; 61(5):994-1003. PubMed ID: 22405510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis.
    Gacci M; Ficarra V; Sebastianelli A; Corona G; Serni S; Shariat SF; Maggi M; Zattoni F; Carini M; Novara G
    J Sex Med; 2014 Jun; 11(6):1554-66. PubMed ID: 24708055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tadalafil - a therapeutic option in the management of BPH-LUTS.
    Carson CC; Rosenberg M; Kissel J; Wong DG
    Int J Clin Pract; 2014 Jan; 68(1):94-103. PubMed ID: 24341303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-blockers with or without phosphodiesterase type 5 inhibitor for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis.
    Zhang J; Li X; Yang B; Wu C; Fan Y; Li H
    World J Urol; 2019 Jan; 37(1):143-153. PubMed ID: 29948047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both?
    Carson CC
    BJU Int; 2006 Apr; 97 Suppl 2():39-43; discussion 44-5. PubMed ID: 16507053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacological treatment of benign prostatic hyperplasia].
    Oelke M; Martinelli E
    Urologe A; 2016 Jan; 55(1):81-94; quiz 95-6. PubMed ID: 26676726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatments of erectile dysfunction combined with lower urinary tract symptoms associated with benign prostatic hyperplasis].
    Jin Z; Xin ZC
    Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Aug; 43(4):632-5. PubMed ID: 21844982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.